Navigation Links
NPS Pharmaceuticals Reports Third Quarter 2007 Financial Results, Revises Financial Guidance
Date:11/1/2007

,744 7,482 17,667 42,405

Restructuring

charges 1,013 2,228 12,252 8,240

Gain on sale of

fixed assets (6,459) - (6,459) -

Gain on sale of

assets held for sale - - (1,826) -

Total operating

expenses 7,749 24,734 55,993 108,577

Operating income

(loss) 21,412 (14,663) (3,726) (84,141)

Other expense, net (7,323) (6,416) (18,136) (14,542)

Income (loss)

before income

tax expense $14,089 $(21,079) $(21,862) $(98,683)

Income tax expense - - - -

Net income

(loss) $14,089 $(21,079) $(21,862) $(98,683)

Net income (loss) per

common and potential

common share:

Basic $0.30 $(0.45) $(0.47) $(2.13)

Diluted $0.28 $(0.45) $(0.47) $(2.13)

Weighted average common

and potential common

shares outstanding:

Basic 46,841 46,435 46,729 46,329

Diluted 52,396 46,435 46,729 46,329

NPS PHARMACEUTICALS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(In thousands)

(Unaudited)

September 30, December 31,

2007 2006

Cash, cash equivalents and marketable

investment securities $302,229 $146,152

Current restricted cash and cash equivalents 16,246 21,921

Account r
'/>"/>

SOURCE NPS Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Deltanoid Pharmaceuticals begins phase II osteoporosis study
2. The Coming of Biotech Generic Pharmaceuticals
3. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
4. Sonic Foundry reports GAAP loss as Q2 revenues rise
5. Fiserv reports $113.5 million in Q1 profit
6. Third Wave reports net loss of $18.9M for 2006
7. Musicnotes reports 45 percent growth in 2006
8. Sonic Foundry reports net loss, higher revenue
9. Sonic Foundry reports first cash-positive quarter
10. Merge Healthcare reports $10.8M net loss in Q3
11. Third Wave reports $5.2M third quarter loss
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/16/2015)... San Francisco, CA (PRWEB) April 16, 2015 ... is scheduled to report first quarter results on Thursday, ... the announcement, Cytokinetics’ senior management will host a conference ... and financial results and the company’s outlook for the ... and can be accessed from the homepage and in ...
(Date:4/16/2015)... 16, 2015 According to the ... an outside source was ranked first among the ... related to lifting, pushing, pulling, holding, carrying, or ... costs. The David Round Company takes statistics like ... working hard to develop and design equipment that ...
(Date:4/16/2015)... 16, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ... joint venture with G-treeBNT (ReGenTree LLC) has retained ... trial for the orphan disorder, neurotrophic keratopathy (NK), ... eye syndrome (DES) in the U.S.  Both trials ... this year.  Each of these eye disorders was ...
(Date:4/16/2015)... Calif. , April 16, 2015  Scientists from ... "New Drugs on the Horizon," at the American Association ... Philadelphia, PA on Sunday, April 19, 2015 ... Ph.D., Cleave,s Director of Biology, will present new in ... a first-in-class, oral inhibitor of p97, a critical enzyme ...
Breaking Biology Technology:Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 2RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 3RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 4RegeneRx JV Retains Ora, Inc. to Conduct Phase 3 Trial for NK and Phase 2b/3 Trial for Dry Eye Syndrome in U.S. 5Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 2Cleave Biosciences to Participate in Special Session "New Drugs on the Horizon" at AACR Annual Meeting 2015 3
... will receive the Johnson & Johnson Dr. Paul Janssen Award ... a series of events that celebrate his central role in ... signaling molecule of angiogenesis. His research has opened the door ... combat a serious eye disorder and contributed to the development ...
... 13Researchers at Vanderbilt University have developed a new technique that ... tissue at multiple points simultaneously, a method that could help ... and change shape. UV lasers are a commonly-used ... incisions by vaporizing one point at a time in a ...
... 2011 Saladax Biomedical, Inc., a privately held company ... promise of personalized medicine for new and existing therapeutics, ... of Saladax, will be presenting at the Annual UBS ... York in New York City on Tuesday, September 20, ...
Cached Biology Technology:Johnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research 2Johnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research 3Johnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research 4Johnson & Johnson Symposium Honors 2011 Recipient of The Dr. Paul Janssen Award for Biomedical Research 5Saladax Biomedical, Inc. to Present at the Annual UBS Global Life Sciences Conference in New York City 2
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)...  In the 2014 fiscal year, irs.gov recorded over ... figure accounts for a fraction of the estimated losses ... exceeds $11 billion globally. The polygraph has traditionally been ... occurred. Investor Mark Saint Juste along with ... partnered to administer the test in a new ...
(Date:3/20/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/rswjb4/hand_geometry ) has announced ... Business Report" report to their offering. This ... Thousands. The report provides separate comprehensive analytics for the US, ... Europe , Asia-Pacific , ... Annual estimates and forecasts are provided for the ...
Breaking Biology News(10 mins):Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... of poor rice farmers and consumers in Asia have received ... While the world's trading nations remain deadlocked on how to ... farmers of the developing world, research just published has confirmed ... planet's two most populous countries, China and India. , The ...
... damaged heart muscle tissue . . . regenerate injured bone ... . even reverse nerve damage. Human stem cells offer tremendous ... and a variety of other human health problems. , Up ... ethical controversy -- as well as by the rarity of ...
... emerged field of bacterial riboswitches may be a good ... to a report by Yale researchers in the journal ... control gene expression in essential metabolic pathways. Researchers in ... Henry Ford II Professor of Molecular, Cellular and ...
Cached Biology News:Some good news for the world's poor 2Some good news for the world's poor 3Some good news for the world's poor 4From one cell, many possible cures 2From one cell, many possible cures 3Switching to new anti-bacterial targets: Riboswitches 2
... Note: Protein determined by Biuret. ... M (NH 4 ) 2 ... Preparation Note: Affinity purified • ... • Additives: MgCl 2 1 ...
... The mir Vana miRNA Bioarray Essentials ... for hybridization and post-hybridization washing of the ... preparation that has been labeled using Ambions ... includes a positive control miRNA (Bioarray ID BA10001) ...
... Tracker Intracellular Localization Kit with TransIT-siQUEST ... approach to directly label and deliver ... efficient yet non-destructive manner, for in ... functional inhibition of target gene expression ...
... extracellular matrix (ECM) is an important step ... invasion by adhering to and spreading along ... such as MMP collagenases, dissolve tiny holes ... the blood vessels to allow cancer cells ...
Biology Products: